In 1961, Leonard Hayflick reported that human fibroblasts cultured in vitro multiplied only a limited number of times, rather than reproducing limitlessly as previously thought. The limited-time of the proliferation of cells is the "Hayflick Boundary." This is also the first theory of aging.
Cellular senescence, also known as cell aging, is a highly stable cell cycle arrest or withdrawal that occurs under different stressful conditions. And cellular senescence is ubiquitous in various organisms. It can permanently inhibit growth and prevent cell proliferation. The cells in the quiescent phase just temporarily exit the cell cycle and they will enter the cell cycle once they receive mitogenic signal. However, the growth arrest of senescent cells is irreversible. It means that senescent cells cannot re-enter the cell cycle even under favorable growth conditions. But their metabolism is still ongoing.
Cellular senescence refers to the senescence of one or more cells. Individual aging is the aging of living organisms. For single-celled organisms, cellular senescence is almost synchronous with individual aging. However, the cellular aging of multicellular organisms does not mean that individuals will age. Individual aging can reflect that most cells are senescent to some extent.
A distinct feature of aging cells is their stable cell cycle arrest. Senescent cells normally undergo chromatin rearrangement, metabolic reprogramming such as the increase of glycolysis, mitochondrial function, and autophagy. Aging cells become flattened, enlarged, and vacuolated. Senescent cells also form cytoplasmic bridges that allow them to signal neighboring cells through intercellular proteins.
The cellular aging pathway is activated by various triggers. In the short term, cellular senescence exhibits beneficial aspects such as the promotion of embryonic development ＆ wound healing and tumor suppression. However, in the late stage of cell injury, cellular aging brings catastrophic consequences like promoting tumorigenesis and inducing aging-related diseases.
During cell senescence, two tumor suppressor pathways - p53/p21CIP1 and p16INK4a/Rb are responsible for cell growth arrest.
Inducing factors of cellular senescence such as telomere loss ＆ the DNA damages caused by carcinogenic or oxidative stress. DNA damages activate a kinase cascade of ATM/ATR/CHK1/CHK2, which ultimately leads to activation of p53. P53 induces transcription of the cyclin-dependent kinase inhibitor (CDKI) p21CIP1. p21CIP1 and then inhibits CDK4/6 activity, resulting in the conversion of the phosphorylated Rb protein to a low phosphorylated or dephosphorylated form. The non-phosphorylated Rb protein binds to the transcriptional regulator E2F, preventing E2F from activating the genes expression that is necessary for the cell cycle. Therefore, cells cannot enter the S phase through the G1 checkpoint, resulting in C0/G1 cell arrest, which initiates cellular senescence.
p16INK4a inhibits CDK4/6-cyclin D activity by binding to CDK4/6, causing a conformational change in CDK4/6. Inactivated CDK4/6-cyclin D inhibits phosphorylation of Rb, enhancing the binding of Rb to E2F. The process inhibits the cell cycle from G1 to S phase. Studies have found that the senescent cells mainly contain the G1 phase DNA content. So it is considered that the senescent cells are arrested in the G1 phase. The senescent cells cannot successfully enter the S phase to initiate chromosome replication to complete the cell cycle.
Since cell aging is associated with a large number of diseases and pathological processes, so many studies are focused on controlling diseases by promoting or inhibiting cell senescence. Some methods have been successful in mouse disease models, and some excellent clinical studies are ongoing. Bcl-2 (B-cell lymphoma 2) is a member of the Bcl-2 family of regulator proteins that modulate apoptosis by inhibiting anti-apoptotic proteins or inducing pro-apoptotic proteins. Inhibitors of BCL-2 are widely used to induce apoptosis in senescent cells. Besides, drugs that induce cellular senescence can also be used as anticancer drugs, including CDK4/6 inhibitors such as palbociclib.
Many studies have confirmed that cell aging plays an important role in the development of chronic diseases, organ failure, and poor prognosis. Therefore, the markers of cell aging are expected to be used for disease diagnosis. And cell senescence may also be a potential drug target for disease treatment. Cellular aging also has a beneficial side for chronic diseases. For example, senescent hepatic stellate cells and cardiac fibroblasts can reduce fibrosis of the corresponding organs and limit disease progression.
|CCND3||CCND3 Antibody||CCND3 Protein||CCND3 cDNA||CCND3 ELISA Kit|
|CCNE1||CCNE1 Antibody||CCNE1 Protein||CCNE1 cDNA||CCNE1 ELISA Kit|
|CCNE2||CCNE2 Antibody||CCNE2 Protein||CCNE2 cDNA||CCNE2 ELISA Kit|
|CDC25A||CDC25A Antibody||CDC25A Protein||CDC25A cDNA||CDC25A ELISA Kit|
|CDK1||CDK1 Antibody||CDK1 Protein||CDK1 cDNA||CDK1 ELISA Kit|
|CDK2||CDK2 Antibody||CDK2 Protein||CDK2 cDNA||CDK2 ELISA Kit|
|CDK4||CDK4 Antibody||CDK4 Protein||CDK4 cDNA||CDK4 ELISA Kit|
|CDK6||CDK6 Antibody||CDK6 Protein||CDK6 cDNA||CDK6 ELISA Kit|
|CDKN1A||CDKN1A Antibody||CDKN1A Protein||CDKN1A cDNA||CDKN1A ELISA Kit|
|CDKN2A||CDKN2A Antibody||CDKN2A Protein||CDKN2A cDNA||CDKN2A ELISA Kit|
|CDKN2B||CDKN2B Antibody||CDKN2B Protein||CDKN2B cDNA||CDKN2B ELISA Kit|
|CHEK1||CHEK1 Antibody||CHEK1 Protein||CHEK1 cDNA||CHEK1 ELISA Kit|
|CHEK2||CHEK2 Antibody||CHEK2 Protein||CHEK2 cDNA||CHEK2 ELISA Kit|
|CXCL8||CXCL8 Antibody||CXCL8 Protein||CXCL8 cDNA||CXCL8 ELISA Kit|
|E2F1||E2F1 Antibody||E2F1 Protein||E2F1 cDNA||E2F1 ELISA Kit|
|E2F2||E2F2 Antibody||E2F2 Protein||E2F2 cDNA||E2F2 ELISA Kit|
|E2F3||E2F3 Antibody||E2F3 Protein||E2F3 cDNA||E2F3 ELISA Kit|
|E2F4||E2F4 Antibody||E2F4 Protein||E2F4 cDNA||E2F4 ELISA Kit|
|E2F5||E2F5 Antibody||E2F5 Protein||E2F5 cDNA||E2F5 ELISA Kit|
|EIF4EBP1||EIF4EBP1 Antibody||EIF4EBP1 Protein||EIF4EBP1 cDNA||EIF4EBP1 ELISA Kit|